Galapagos finds little comfort in safety
Filgotinib’s mixed efficacy in ulcerative colitis prompts a shares slide.
Moderna reminds the markets of biotech’s dual purpose
On the back of coronavirus mania, Moderna, a $30bn company heavily funded by the US government, taps investors for $1.3bn.
Viiv’s HIV success shows PrEP is not everything
Gilead’s dominance of the HIV prevention market is set to be challenged by monotherapy.
Genfit’s predictable liver disease failure sets up a cirrhosis pivot
Five years after failing phase II in Nash, elafibranor fails phase III in Nash; a focus on liver cirrhosis beckons.
Remember Chantix? It’s back – for dry eye disease
The smoking-cessation drug, reformulated for nasal delivery, could be launched for dry eye, Oyster Point hopes.
Macrogenics scoops its Asco bounce
A tiny glimpse at very early data has more than tripled Macrogenics’ market cap. The pressure is now on to confirm these signals.
TG pulls victory from the jaws of defeat
The Unity-CLL trial shows ublituximab plus umbralisib conferring an unexpected progression-free survival benefit.
Novo’s Nash play takes shape
As semaglutide looks set to move into pivotal trials in Nash, Novo Nordisk lays out hopes for longer-term benefits.
Akebia confirms its place in the anaemia race
Two successful pivotal trials with vadadustat put Akebia on track to file its novel anaemia pill by year end – hot on the heels of Fibrogen.
